A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Bevacizumab Compared to Bevacizumab With 5-FU in Participants with Unresectable or Metastatic Colorectal Cancer who Have not Progressed Following First-line Induction of FOLFOX With Bevacizumab (LYNK-003)

  • Strickland, Andrew (Primary Chief Investigator (PCI))

Project: Research

Project Details

StatusFinished
Effective start/end date12/08/20 → 11/08/25

Keywords

  • clinical trial
  • treatment safety
  • treatment efficacy
  • colorectal cancer treatment
  • colorectal cancer

Clinical Trial Phase

  • Phase III (a & b)